For many years, physicians and the public assumed that the discovery of new antimicrobial agents would outpace the ability of bacteria to mutate and develop drug resistance. Yet the development of new antibiotics has not kept up with bacterial evolution, especially since the late 1990’s. At that time a multitude of pharmaceutical companies abandoned antibiotic research because of strong economic disincentives. For example, it is challenging for these companies to recuperate the investment (typically in the hundreds of millions of dollars) made in developing a new antibiotic, which is typically prescribed for a few days, compared to drugs that treat chronic conditions like heart disease or mental illness. This situation has led the U.S. federal government to take a more active lead in addressing antibiotic resistance. Recently, the White House announced an action plan that includes improving surveillance, developing better diagnostic tools, accelerating drug development, and improving global coordination of antibiotic resistance issues. Equally important is the $1.2 billion dollars that has been pledged to fund these efforts. While we await the implementation of new policies, this issue of Infectious Disease Clinics of North America brings together leading authorities in the field of antibiotic resistance who discuss current issues including antibiotic stewardship, the changing role of the microbiology laboratory in determining antibiotic resistance in gram-negative pathogens, the continuing spread of metallo-β-lactamases, ESBLs and KPCs, antibiotic options for treating resistant gram-negative infections such as colistin and tigecycline, resistance mechanisms and new treatment options for Mycobacterium tuberculosis, emerging resistance mechanisms in aminoglycosides, issues with antibiotic resistance in immunocompromised patients, new β-lactamase inhibitors in the clinic, and resistance in VRE and Staphylococcus aureus. Additionally, combination therapy for resistant gram-negative infections has been advocated by some authorities and the advantages and disadvantages of this strategy will be reviewed.
Costelloe C, Metcalfe C, Lovering A. Effect of antibiotic prescribing in primary care on antimicrobial resistance in individual patients: systematic ... Infectious diseases physicians: leading the way in antimicrobial stewardship.
Management of multidrug-resistant organisms in health care settings, 2006. Am J Infect Control 2007 ... Guidance for control of infections with carbapenem-resistant or carbapenemase-producing enterobacteriaceae in acute care facilities.
Attributable cost of nosocomial primary bloodstream infection in pediatric intensive care unit patients. Pediatrics 2005;115(4):868–72. 48. Alahmadi YM, Aldeyab MA, McElnay JC, et al. Clinical and economic impact of contaminated blood ...
International study of the prevalence and outcomes of infection in intensive care units. ... Bryant AE, Bayer CR, Aldape MJ, McIndoo E, Stevens DL. ... The Pediatric infectious disease journal 1999;18(12):1096–100. 93.
Needle exchange programs (NEPs) FAQs 2004. 29. Dolan K, Kimber J, Fry C, et al. Drug consumption facilities in Europe and the establishment of supervised injecting centres in Australia. Drug Alcohol Rev 2000;19(3):337–46. 30.
This document can serve as a reference for anyone looking for information about antibiotic resistance. For more technical information, references and links are provided. Figures. This is a print on demand report.
Single-molecule sequencing to track plasmid diversity of hospital-associated carbapenemase-producing Enterobacteriaceae. Sci Transl Med 2014;6(254):254ra126. Centers for Disease Control Prevention (CDC). Vital signs: carbapenemresistant ...
Renaud C, Harrison CJ. Human parechovirus 3: the most common viral cause of meningoencephalitis in young ... Pruss H, Finke C, Holtje M, et al. ... Perez-Velez CM, Anderson MS, Robinson CC, et al. Outbreak Encephalitis in US Children ...
The Resistance Phenomenon in Microbes and Infectious Disease Vectors examines our understanding of the relationships among microbes, disease vectors, and human hosts, and explores possible new strategies for meeting the challenge of ...
Infectious Disease physicians and anyone in the hospital setting will find this issue very useful, as state-of-the-art clinical reviews provide clinical management on these common and emerging infections.